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Abstract 
The CD103+ integrin is an adhesion molecule found on > 95% of intra-epithelial mucosal lymphocytes, 
but on <2% of circulating lymphocytes. Several studies have shown that the proportion of CD4+ 
lymphocytes expressing the CD103+ integrin (CD103+CD4+/CD4+ ratio) in bronchoalveolar lavage 
fluid (BALF) was low in sarcoidosis compared to other interstitial lung diseases, but we previously 
demonstrated that the difference was insufficient to allow a confident diagnosis of sarcoidosis without 
tissue biopsy. Whether BALF CD103+CD4+/CD4+ ratio could have prognostic value in sarcoidosis is 
unknown. To address this issue, we examined the associations between BALF CD103+CD4+/CD4+ ratio 
and clinical and imaging characteristics in a retrospective series of 115 patients with sarcoidosis. 63% 
were men, with a median age of 48 years. 47% had radiographic stage I, 49% had stage II, and 4% had 
stage III or IV. The median BALF lymphocyte count was 43% and the median CD103+CD4+/CD4+ ratio 
was 17%. A higher CD103+CD4+/CD4+ ratio was significantly associated with a higher radiographic 
stage at diagnosis (p=0.017) and last visit (p<0.0001), as well as the presence of fibrosis at imaging at 
diagnosis (p=0.043) and last visit (p=0.032). Besides an inverse correlation with forced vital capacity 
at diagnosis (β=-0.16, p=0.031), no consistent association was found between the BALF 
CD103+CD4+/CD4+ ratio at diagnosis and lung function parameters at diagnosis and last visit. We 
conclude that BALF CD103+CD4+/CD4+ ratio may have prognostic value in sarcoidosis. 
  
3 
 
Introduction  
Sarcoidosis is a multisystemic disease, characterized by the formation of non-caseating granulomas in 
various organs [1],  and involves the lungs in more than 90% of cases [2, 3].  The disease causes remain 
unknown, but genetic and environmental factors play a role [4-6]. The clinical presentation is 
heterogeneous, and symptoms are variable according to the affected organs. There are two main 
types of onsets in thoracic sarcoidosis: an acute onset associated with better prognostic and high rate 
of spontaneous remission, and a chronic onset  characterized by more insidious organ involvement, 
less systemic symptoms and more relapses [3]. The overall mortality of sarcoidosis is 1-5%, most of 
the time due to pulmonary failure or secondary to cardiac or neurological involvement [1].  
The diagnosis of thoracic sarcoidosis is based on a compatible clinical picture and chest imaging, the 
presence of non-caseating granulomas at tissue biopsy or cytology, and the exclusion of other diseases 
with similar histological or clinical presentation. Patients with pathognomonic Löfgren syndrome 
characterized by bilateral hilar lymphadenopathy, ankle arthritis and erythema nodosum do not need 
a histological confirmation [3, 7]. The bronchoalveolar lavage fluid (BALF) is characterized by 
lymphocytic alveolitis with CD4+ T-cell predominance [8, 9]. A CD4/CD8 ratio > 3.5 has been reported 
to have sensitivity of 94% for the diagnosis of sarcoidosis [10]. 
The CD103+ integrin is an adhesion molecule found on > 95% of intra-epithelial mucosal lymphocytes, 
but <2% of circulating lymphocytes [11, 12]. Previous studies have suggested that the 
CD103+CD4+/CD4+ ratio in BALF is lower in sarcoidosis compared to other interstitial lung diseases 
(ILD) [13-15], which was attributed to a redistribution of peripheral blood CD4 lymphocytes to the 
lungs [16]. It was further suggested that a CD103+CD4+/CD4+ ratio below 31% could allow to 
confidently diagnose pulmonary sarcoidosis in the absence of biopsy [15], but we previously 
demonstrated that this ratio is insufficient to accurately discriminate between sarcoidosis and other 
ILD [13]. However, in exploratory analyses, we found an inverse relationship between the 
CD103+CD4+/CD4+ ratio and forced vital capacity (FVC), total lung capacity (TLC) and the carbon 
monoxide diffusing capacity (DLCO) at last visit, suggesting that the CD103+CD4+/CD4+ ratio could 
have a prognostic value. Another study by Lohmeyer [17] also found that patients with stage 1 
sarcoidosis had a lower CD103+CD4+/CD4+ ratio than patients with stages 2, 3, and 4.  
The aim of this study was therefore to determine whether BALF CD103+CD4+/CD4+ ratio at diagnosis 
could have prognostic value in sarcoidosis. 
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Methods 
Case recruitment and data collection 
Results of BALF flow cytometry performed between January 2006 and October 2018 at the Institute 
of Pathology of the Lausanne university hospital were retrospectively reviewed. These analyses have 
been routinely performed since 2006 on all BALF samples having >20% lymphocytes on differential 
cell count, and on samples with <20% lymphocytes in patients with immunosuppression or 
hematological malignancies. Cases with mention of poor technical quality (< 10'000 events at flow 
cytometry) were discarded.  For the remaining cases, health records were reviewed for diagnostic 
information. Cases without diagnostic information or with diagnoses other than sarcoidosis were 
removed, and only cases with a well-defined diagnosis of sarcoidosis were included. The diagnosis of 
sarcoidosis required compatible clinical and imaging features and the presence of non-caseating 
granulomas on tissue biopsy or transbronchial needle aspiration cytology of mediastinal lymph nodes. 
Patient with a pathognomonic Löfgren’s syndrome in the absence of histological or cytological sample 
were also included. For cases with BALF flow cytometry performed at our institution but followed 
outside, we contacted the respiratory physician who performed the bronchoscopy to retrieve clinical 
information. 
Collected data included demographic information, BALF cytology, radiographic stage at diagnosis and 
at last visit, the presence of parenchymal fibrosis at chest computed tomography at diagnosis and last 
visit, lung function at diagnosis and last visit, extrapulmonary organ involvement, the need for 
systemic treatment, and the clinical phenotype according to the 6 categories proposed by Prasse et 
al. [18].  
Bronchoalveolar lavage fluid analysis and flow cytometry 
The method of BALF analysis has been previously described [13]. In brief, BALF was collected in sterile 
bottles during regular diagnostic work-up and filtered through gauze. Ten milliliters of sample were 
cytocentrifuged, then smeared and stained with May-Grünwald, Giemsa, modified Papanicolaou, 
Prussian Blue, Gram-Weigert, and Ziehl-Neelsen as needed. For differential cell count, a sample 
corresponding to 250’000-300’000 cells was passed through a multipore filter. After staining with 
modified Papanicolaou, a minimum of 2x100 cells were counted. For flow cytometry, 10-30 ml of 
native sample were centrifuged, decanted and resuspended in NH4Cl or Roswell Park Memorial 
Institute medium several times until reaching a cellularity of 2 x 106. The cells were stained with 
fluorochrome-labelel monoclonal antibodies (Dako Denmark A/S, Glostrup, Denmark) for CD45 (FITC 
clone T29/33), CD4 (RPE, clone MT310), CD8 (FITC, clone DK25), and CD103 (FITC, clone Ber-ACT8) 
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following a standard protocol, and 5-color flow cytometric analysis was performed (Navios Beckman 
Coulter flow cytometer). 
Statistical analyses 
Continuous variables were expressed as mean, median, standard deviation (SD) and interquartile 
range (iqr), and categorical variables were described as percentage. Six explanatory variables (age at 
diagnosis, sex, radiographic stage at diagnosis, percentage of CD103+CD4+/CD4+, CD4/CD8 ratio, and 
percentage of BALF lymphocytes) were correlated with the following outcome variables, both at 
diagnosis and at last visit: forced expiratory volume in one second (FEV1), FVC, total lung capacity 
(TLC), residual volume (RV), DLCO, presence of fibrosis at chest high-resolution computed tomography 
(HRCT), and radiographic stage. Correlations were also made with the 6-category disease phenotype 
as proposed by Prasse et al. [18]. Robust regression and logistic regression were used for these 
analyses. Statistics were performed with Stata. Patient’s consent was waived. The study was approved 
be the Ethics committee of canton Vaud (CER-VD 2017-01784). 
 
Results 
Study population 
Case selection is summarized in Figure 1. Seven hundred and twenty-six BALF were analyzed by flow 
cytometry at the Institute of Pathology between 1.1.2006 and 30.10.2018. One hundred and sixty of 
them were of insufficient quality and were excluded. For the remaining 566 cases, electronic health 
records were reviewed for diagnostic information: 274 patients had a disorder other than sarcoidosis, 
and 104 had a diagnosis of sarcoidosis. However, 15 of them had neither histological confirmation nor 
Löfgren’s syndrome and were excluded, leaving 89 cases of proven sarcoidosis. For 188 out of 566 
patients, diagnostic information was not available in electronic health records as they had only BALF 
analysis performed at the Institute of Pathology but were followed outside the institution. Diagnostic 
information could be retrieved by contacting their physician in 78/188 (41%), and 26 of them had 
sarcoidosis with sufficient clinical data to allow inclusion, and were added to the 89 institutional cases. 
Thus, 115 patients constituted the study population. 
Patient characteristics 
Table 1 summarizes patient characteristics at diagnosis and at last visit. The median age at diagnosis 
was 48 years and 73/115 (63%) were men. The median CD103+CD4+/CD4+ ratio was 17%, the median 
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CD4/CD8 ratio was 4, and the median BALF lymphocyte count was 43%. At diagnosis, 47% had 
radiographic stage 1, 49% had stage 2, and 4% had stages 3 or 4. A last visit, 30% had normal chest X-
ray, 37% had stage 1, and only 20% had stage 2, but the proportion of stages 3 or 4 increased to 13%. 
The percentage of patients with fibrosis at HRCT increased from 9% at diagnosis to 14% at last visit.  
The most common phenotype according to Prasse, found in 44%, was phenotype 4 (subacute onset 
and no need for systemic treatment). The second most common phenotype, found in 22%, was 
phenotype 6 (subacute onset, and need for several courses of therapy or treatment lasting more than 
one year). Twenty-four percent had acute disease onset (phenotypes 1, 2 and 3) and 76% had 
subacute onset (phenotypes 4, 5 and 6). Fifty-five percent did not require corticosteroid therapy 
(phenotypes 1 and 4), whereas 14% required one period of treatment for no longer than one year 
(phenotypes 2 and 5), and 31% required several course of therapy or a treatment longer than one year 
(phenotypes 3 and 6).  
Analysis of variables at diagnosis 
The CD103+CD4+/CD4+ ratio was significantly associated with age (b=0.493, p=0.001), whereas the 
CD4/CD8 ratio, and BALF lymphocyte count were not (data not shown).  
Table 2 shows the associations between explanatory variables and lung function at diagnosis. Age and 
sex were not associated with any lung function parameter, except for a positive correlation between 
age and residual volume at diagnosis (p=0.042). Higher CD103+CD4+/CD4+ ratio was only associated 
with lower FVC (p=0.031), but no association was found with other lung function parameters at 
diagnosis. The CD103+CD4+/CD4+ ratio was also positively correlated with the age at diagnosis 
(p=0.001). No significant association was found between the CD4/CD8 ratio and initial lung function. 
An inverse relationship was found between BALF lymphocytes and both FEV1 (p=0.01) and DLCO 
(p=0.014). The most consistent associations were found between radiographic stage and lung function 
at diagnosis. Indeed, higher radiographic stages were significantly correlated with lower FEV1, lower 
FVC, lower TLC, and lower DLCO (table 2).  
Relationships between explanatory variables and radiographic stage at diagnosis are shown in table 
3. Higher CD103+CD4+/CD4+ ratio was associated with higher radiographic stage (p=0.017), whereas 
no such association was found for CD4/CD8 ratio, BALF lymphocytes count, age and sex. 
Correlations between explanatory variables and presence of fibrosis at HRCT at diagnosis are shown 
in table 4. Presence of fibrosis was associated with higher CD103+CD4+/CD4+ ratio (p=0.043), whereas 
CD4/CD8 ratio, BALF lymphocyte count, age and sex did not correlate with the presence of fibrosis. 
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Radiographic stage at diagnosis was strongly associated with the presence of fibrosis at HRCT (table 
4). 
No association was found between the CD103+CD4+/CD4+ ratio and type of disease onset according 
to Prasse, either acute (phenotypes 1, 2 and 3) or subacute (phenotypes 4, 5 and 6) (table 5). Acute 
disease onset was associated with higher CD4/CD8 ratio (median 5.0 vs 3.5, p=0.014) and younger age 
(42.9 vs 50.0, p=0.007).  
Analysis of variables at last visit 
Table 6 shows the associations between explanatory variables at diagnosis and lung function at last 
visit. Men had significantly higher DLCO at last visit (p=0.012), and younger age at diagnosis was 
associated with higher DLCO (p=0.045) at last visit. The CD103+CD4+/CD4+ ratio at diagnosis was not 
associated with any lung function parameter at last visit. Lower BALF lymphocyte count at diagnosis 
was correlated with higher FEV1 at last visit (p=0.018) but there was no association with other lung 
function parameters. Initial radiographic stage was not significantly correlated with lung function at 
last visit.  
Associations between explanatory variables at diagnosis and radiographic stage at last visit are shown 
in table 7. The CD103+CD4+/CD4+ ratio at diagnosis was strongly associated with the radiographic 
stage at last visit (p<0.0001). The CD4/CD8 ratio was negatively correlated with the radiographic stage 
(p=0.003). 
Associations between explanatory variables at diagnosis and presence of fibrosis at last visit are shown 
on table 8. Higher CD103+CD4+/CD4+ ratio at diagnosis was associated with presence of fibrosis at 
last visit (p=0.032), whereas no such relationship was found for CD4/CD8 ratio, BALF lymphocyte 
count, age and sex. Higher radiographic stage at diagnosis was significantly associated with presence 
of fibrosis (table 8). 
 
Discussion 
The main finding of the present study is that, in sarcoidosis, the BALF CD103+CD4/CD4+ ratio at 
diagnosis is associated with radiographic stage and the presence of parenchymal fibrosis at chest 
imaging, both at diagnosis and at last visit. This suggests that this ratio has prognostic value in 
sarcoidosis, and might be a parameter of interest during the initial work-up of patients with this 
disease. 
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From our previous study [13], we expected to find a correlation between the values of the lung 
functions at the last visit and the CD103+CD4/CD4+ ratio in the initial BALF. This present study showed 
a deterioration in the lung function in patients with higher CD103+CD4+/CD4+ ratio but the inverse 
correlation was not significant. As the first study was done on a smaller amount of patients, it was 
necessary to verify this finding on a larger pool of patients. Another explanation could be the gap 
between the BALF and the last visit, since there was no fixed interval and some of the patients had 
lung functions ten years after the BALF. Moreover, no distinction was made between patients 
receiving treatment and the ones with spontaneous remission. According to Judson [19] the lung 
functions are improved with time and therapy, thus, it could be an explanation for the differences in 
the results. The FVC at diagnosis is the only lung function parameter significantly correlated with the 
CD103+CD4+/CD4+ ratio. This isolated correlation is hard to explain. 
However, as expected from the study of Lohmeyer [17], a significant correlation was found between 
the CD103+CD4+/CD4+ ratio and the radiological stage, not only at diagnosis but also at the last visit 
–the correlation being even stronger at the last visit. This means that patients with a low 
CD103+CD4+/CD4+ ratio have a better radiological stage at diagnosis but also an improvement of the 
radiological impairment during the following years. As the radiological stage is known to be a 
prognostic marker [20], the CD103+CD4+/CD4+ ratio, being lower with lower radiological stage, 
should also have a prognostic value. This could also explain the disagreements found in the different 
studies about the diagnostic value of the CD103+CD4+/CD4+ ratio. Studies having a high proportion 
of patients with radiological stage I had a higher probability of finding lower CD103+CD4+/CD4+ ratio 
in patients with sarcoidosis and use it for a discriminative diagnosis purpose. For example, Heron [14] 
in his study had 49% of patient with sarcoidosis with a radiological stage I. 
Several studies tried to understand the role of the CD103 integrin in inflammatory and pro-fibrotic 
processes and its link with TGF-beta, but the phenomenon is not yet fully understood. Rhis [21] 
showed that the presence of the TGF-beta, known to be implicated in fibrosis [22], increases the 
expression of the CD103 integrin, especially on CD8 lymphocytes. On CD4 lymphocytes, undetermined 
factors seem to play an additional role in the increase of CD103. The article written by Zissel [23] 
confirms the correlation between the level found of TGF-beta in the BALF and the induction of a 
spontaneous remission in patient with sarcoidosis. The level of TGF-beta seems also to increase after 
the beginning of corticosteroid therapy. Both speaking for a positive effect of the TGF-beta and in 
contradiction with the fibrotic effect previously described. Zissel offers different explanations for 
these differences : the level of TGF-beta found in the BALF do not reflect the active level of the TGF-
beta in the lung, the TGF-beta impact depend on the fibroblast, the TGF-beta may be necessary for 
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the induction of fibrosis but not sufficient – which joins the observation of Rhis described above about 
the necessity of additional mechanisms to induce the CD103 on CD4 lymphocytes. 
As for the CD103 integrin itself, several studies explored the pro-inflammatory role of the 
CD103+CD4+/CD4+ ratio in BALF and its link with the presence of fibrosis in lung diseases, and 
observed a higher ratio in patients with fibrotic lung diseases as compared to other lung diseases [17, 
21]. These findings are consistent with our present study, which shows a significantly higher 
CD103+CD4+/CD4+ ratio in patients with signs of fibrosis at chest imaging. Therefore, our study 
confirms a link between the BALF CD103+CD4+/CD4+ ratio at diagnosis and occurrence of fibrosis in 
pulmonary sarcoidosis, and suggests that this ratio has a prognostic value.  
Our study also confirms the prognostic value of the radiographic stage at diagnosis, which is now well 
established in the literature [20, 24, 25]. Indeed, patients with radiographic stages II and III-IV at 
diagnosis had significantly higher risk of fibrosis at last visit than patients with stage I. 
Unsurprisingly, lung function parameters at diagnosis were lower in patients with radiographic stage 
II or III-IV compared to stage I, except for RV (table 2). One possible explanation for the lack of effect 
on RV could be air trapping,  which was found to be common in sarcoidosis [26] and could counteract 
the restrictive effect of lung parenchyma infiltration by sarcoidosis on RV. Higher initial radiographic 
stages at diagnosis tended to result in lower lung function parameters at last visit, but the differences 
did not reach statistical significance, which could be attributed to the effect of therapy. 
The prognostic role of the CD4/CD8 ratio has been much debated in the literature [27-29]. In our study, 
the ratio is correlated to the radiological stage at the last visit. The association between an high ratio 
and an improvement of the radiological stage was previously observed by Verstraeten [28]. The 
correlation was no longer significant when patients with radiological stage III were excluded from the 
analysis. This exclusion was not done in our study. What emerges from different studies is the 
observation of a high CD4/CD8 ratio in patients with Löfgren’s syndrome. This is explained by the 
activities of the disease. When the disease is acutely active the CD4/CD8 ratio is higher. This 
observation is confirmed in our study, indeed, patients with an acute onset had a significant higher 
CD4/CD8 ratio than patient with a subacute onset. In the literature, the ratio seems also to have a link 
with the response to corticosteroid therapy, patient with a high ratio have a better response to 
treatment [27]. This was not analyzed in our study.  
The last analytic variable in the BALF was the percentage of lymphocytes. The role of the 
lymphocytosis as prognostic factor is debated and the percentage seems to depend on the interval of 
time between the onset of the disease and the BALF [27, 30, 31]. In our study we found a correlation 
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between the percentage of lymphocytosis and the FEV1 at diagnosis and at the last visit as well as a 
diminution of the DLCO but we did not search in our data a link between this percentage and a 
spontaneous remission, which could be interesting for further analyze.  
The age is surprisingly correlated with lung functions, which is hard to explain given that the lung 
functions are expressed in percentage of the value expected for the age. An older age correlates also 
with a subacute onset of the disease. Older patients have a more insidious disease and the 
impairments of the lung function become bigger.  
Conclusion 
This present study suggests that the CD103+CD4+/CD4+ ratio has prognostic value in sarcoidosis. It 
would be interesting to do additional analyses to search a correlation between the ratio and the need 
of therapy. It might make sense to treat patients with a high ratio in order to limit fibrosis but more 
analyzes need to be done.  
Limitation 
The interpretations of the findings at the last visit need to be analyzed with caution, as explained 
above the interval is different from one patient to another. It would have made more sense to 
predefine a time interval between the analyses at diagnosis and the comparison values.  
The study showing a correlation between the age and the CD103+CD4+/CD4+ ratio, more analyzes are 
necessary to confirm that the findings are linked to the ratio itself and not influenced by age. 
The last interesting point is the conclusion made by Ward [31] to explain the contradictory results 
found in the diverse studies on BALF : the results are influenced by the different lavage protocols, 
genetics and racial characteristics of the patients, the onset of the symptoms and the clinical 
presentation. To assert our finding, the analyze should be done in subgroups with theses specific 
criteria.  
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BAL performed at Lausanne University 
Hospital between 1.1.2006 and 
30.10.2018 with available flow 
cytometry 
726 
Eligible cases 
566 
BAL of insufficient 
technical quality 
160 
Diagnosis available 
378 
Diagnosis not available 
at Lausanne university 
hospital 
188 
 
Other diagnoses  
274 
Sarcoidosis 
104 
 
Cases of sarcoidosis collected 
from pulmonologists files 
26 
Unconfirmed diagnosis 
15 
Confirmed sarcoidosis 
89 
 
Cases of confirmed sarcoidosis included in the study 
115 
Figure 1 
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Table 1. Patient characteristics at diagnosis and last visit
n mean SD median n (%) n mean SD median n (%)
age 115 48 12 48
men 115 73 (63)
FEV1, % predicted 102 91 16 94 84 91 18 94
FVC, % predicted 101 98 17 100 84 96 18 97
TLC, % predicted 94 91 16 90 77 92 14 92
RV, % predicted 93 82 34 78 76 86 24 82
DLCO, % predicted 96 82 18 84 78 85 22 89
Radiological stage:
normal CXR 114 0 (0) 91 27 (30)
I 114 53 (47) 91 34 (37)
II 114 56 (49) 91 18 (20)
III-IV 114 5 (4) 91 12 (13)
%CD103/CD4 115 24 21 17
CD4/CD8 ratio 115 5 5 4
% BAL lymphocytes 115 43 18 43
Fibrosis at imaging 115 10 (9) 92 13 (14)
Phenotype*
1 110 12 (11)
2 110 4 (4)
3 110 10 (9)
4 110 49 (44)
5 110 11 (10)
6 110 24 (22)
*according to Prasse. CXR: chest X-ray
At diagnosis At last visit 
13 
 
 
 
  
Table 2. Associations between explanatory variables at diagnosis and initial lung function*
Variable at diagnosis
b p b p b p b p b p
male sex -3.33 0.307 -4.37 0.198 -5.60 0.080 0.89 0.901 6.35 0.114
age 0.017 0.895 0.155 0.255 0.098 0.434 0.57 0.042 -0.22 0.143
BAL CD103/CD4, % -0.097 0.185 -0.16 0.031 -0.109 0.122 0.025 0.874 -0.05 0.566
BAL CD4/CD8 ratio -0.013 0.971 0.20 0.593 0.136 0.698 -0.183 0.817 -0.65 0.141
BAL lymphocytes, % -0.208 0.010 -0.14 0.109 -0.145 0.084 -0.121 0.527 -0.26 0.015
radiographic stage:
I reference reference reference reference reference
II -8.66 0.006 -7.28 0.033 -7.18 0.025 -1.87 0.79 -14.06 <0.0001
III-IV -18.18 0.013 -14.9 0.056 -17.97 0.022 -19.43 0.28 -21.78 0.018
*robust regression
DLCO at diagnosisFEV1 at diagnosis FVC at diagnosis TLC at diagnosis RV at diagnosis
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Table 3. Associations between explanatory variables and radiographic stage at diagnosis
stage  I
(n=53)
 stage II
(n=56)
OR (95% CI) p*
%CD103/CD4, median (iqr) 11 (17) 25 (29) 1.025 (1.004-1.046) 0.017
CD4/CD8, median (iqr) 4.0 (5.2) 3.6 (3.5) 0.932 (0.854-1.018) 0.12
% of lymphocytes, median (iqr) 41 (27) 45 (33) 1.013 (0.992-1.034) 0.213
age, median (iqr) 45.2 (20.1) 50.6 (16.9) 1.007 (0.976-1.039) 0.622
male sex, n (%) 34 (64) 34 (61) 0.863 (0.397-1.877) 0.711
*logistic regression
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Table 4. Associations between explanatory variables and fibrosis at diagnosis
fibrosis absent
(n=105)
fibrosis present 
(n=10)
OR (95% CI) p*
%CD103/CD4, median (iqr) 15 (27) 42 (40) 1.028 (1.001-1.056) 0.04
CD4/CD8, median (iqr) 4.0 (4.3) 2.9 (4.1) 0.887 (0.711-1.105) 0.29
% of lymphocytes, median (iqr) 43 (29) 38 (20) 0.995 (0.960-1.032) 0.8
age, median (iqr) 45.7 (17.4) 53.8 (10.1) 1.033 (0.978-1.090) 0.235
male sex, n (%) 65 (62) 8 (80) 2.461 (0.497-12.177) 0.269
Radiographic stage:
stage I 53 (51) 0 (0) reference
stage II 50 (48) 6 (60) 0.03 (0.0028-0.31) 0.003
stage III-IV 1 (1) 4 (40) ** **
*logistic regression. **radiographic stage I predicts perfectly the outcome
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Table 5. Associations between explanatory variables and disease onset
acute
onseta
(n=26)
subacute
onsetb
(n=84)
OR (95% CI) p*
%CD103/CD4, median (iqr) 11 (23) 20 (29) 1.018 (0.994-1.044) 0.14
CD4/CD8, median (iqr) 5.0 (6.1) 3.5 (4.1) 0.895 (0.820-0.978) 0.014
% lymphocytes, median (iqr) 44 (30) 41 (29) 0.999 (0.976-1.023) 0.984
age, median (iqr) 42.9 (13.6) 50.0 (17.3) 1.059 (1.015-1.105) 0.007
mlae sex, n (%) 15 (58) 55 (66) 1.390 (0.566-3.416) 0.472
radiographic stage at diagnosis:
I 14 (54) 38 (46) reference
II 12 (46) 41 (49) 1.258 (0.517-3.060) 0.612
III-IV 0 (0) 4 (5) ** **
aphenotypes 1, 2, and 3 according to Prasse. bphenotypes 4, 5, and 6 according to Prasse. 
*logistic regression. **radiographic stage III-IV predicts perfectly the outcome
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Table 6. Associations between explanatory variables at diagnosis and lung function at last visit*
Variable at diagnosis
b p b p b p b p b p
male sex -2.19 0.538 -3.03 0.44 -0.64 0.855 7.85 0.225 13.29 0.012
age -0.25 0.062 -0.25 0.080 -0.19 0.139 0.21 0.382 -0.43 0.045
BAL CD103/CD4, % -0.05 0.542 -0.14 0.099 -0.09 0.213 0.08 0.553 -0.07 0.550
BAL CD4/CD8 ratio 0.04 0.912 0.47 0.23 0.19 0.579 -0.031 0.961 -0.76 0.149
BAL lymphocytes, % -0.21 0.018 -0.10 0.304 -0.11 0.247 0.048 0.775 -0.24 0.102
radiographic stage at diagnosis:
I reference reference reference reference reference
II -3.33 0.29 -4.13 0.27 -1.59 0.64 5.90 0.33 -8.42 0.09
III-IV 5.37 0.60 -10.26 0.31 -11.02 0.21 -6.84 0.66 -15.25 0.23
*robust regression
DLCO last visitFEV1 last visit FVC last visit TLC last visit RV last visit
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Table 7. Associations between explanatory variables and radiographic stage at last visit
normal
CXR
(n=27)
stage I
(n=34)
stage II
(n=18)
stage III-IV
(n=12)
OR (95% CI) p*
%CD103/CD4, median (iqr) 10 (26) 18 (31) 31 (28) 45 (32) 1.033 (1.014-1.053) <0.0001
CD4/CD8, median (iqr) 5.6 (6.3) 3.5 (4.1) 3.2 (3.5) 2.6 (3.9) 0.856 (0.772-0.950) 0.003
% of lymphocytes, median (iqr) 44 (39) 44 (24) 48 (20) 32 (15) 0.994 (0.974-1.015) 0.592
age, median (iqr) 45.2 (21.3) 45.5 (25.7) 48.9 (17.2) 53.8 (6.4) 1.005 (0.975-1.035) 0.736
male sex, n (%) 14 (52) 24 (71) 12 (67) 9 (75) 1.812 (0.814-4.031) 0.142
*ordinal logistic regression. CXR: chest X-ray
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Table 8. Associations between explanatory variables and fibrosis at last visit  
  
fibrosis 
absent 
(n=79) 
fibrosis 
present 
(n=13) 
OR ( 95% CI) p* 
%CD103/CD4, median (iqr) 17 (30) 34 (46) 1.028 (1.002-1.055) 0.032 
CD4/CD8, median (iqr) 4.0 (4.0) 2.3 (3.7) 0.859 (0.689-1.071) 0.18 
% of lymphocytes, median (iqr) 45 (31) 36 (16) 0.977 (0.943-1.012) 0.19 
age, median (iqr) 45.7 (17.3) 53.1 (8.8) 1.020 (0.973-1.070) 0.40 
male sex, n (%) 50 (63) 10 (77) 1.933 (0.491-7.600) 0.34 
radiographic stage at diagnosis     
I 40 (52) 1 (8) reference  
II 37 (47) 8 (61) 8.648 (1.031-72.514) 0.047 
III-IV 1 (1) 4 (31) 160 (8.322-3076) 0.001 
*logistic regression     
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